Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Marina Biotech licenses UNA technology to Tekmira
January 2013
SHARING OPTIONS:

BOTHELL, Wash.A license agreement was announced in late November between Marina Biotech Inc. and Tekmira Pharmaceuticals Corp., under which Tekmira will be granted a worldwide, non-exclusive license to Marina Biotech's Unlocked Nucleobase Analog technology for the development of RNA interference therapeutics. Tekmira will be responsible for development and commercialization of any products that result from the deal, and Marina Biotech will receive an upfront payment in addition to being eligible for milestone and royalty payments on resulting products. Financial terms were not disclosed.  
 
"We are pleased to enter into this agreement with Tekmira, a leader in the development of RNAi- based therapeutics We look forward to a continued relationship with the great team at Tekmira," J. Michael French, president and CEO of Marina Biotech, said in a press release.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.